Eli Lilly Seeks FDA Approval for Foundayo in Type 2 Diabetes Patients
Eli Lilly (LLY) plans to seek FDA approval for its obesity drug Foundayo for use in patients with type 2 diabetes in Q2, following successful Phase 3 trial results. The drug, already approved for weight loss, is now being evaluated for a label expansion based on positive trial data.
Tickers: $LLY
Topics: label expansion pharmaceuticals Phase 3 trial type 2 diabetes weight loss drug